Inozyme Return On Equity from 2010 to 2024

INZY Stock  USD 2.81  0.12  4.46%   
Inozyme Pharma Return On Equity yearly trend continues to be fairly stable with very little volatility. Return On Equity is likely to outpace its year average in 2024. Return On Equity is a measure of the profitability of Inozyme Pharma in relation to the equity, calculated by dividing net income by shareholder's equity. View All Fundamentals
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.51)
Current Value
(0.48)
Quarterly Volatility
0.48469881
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.3 M, Interest Income of 4.3 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.65. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.
  
Check out the analysis of Inozyme Pharma Correlation against competitors.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Return On Equity Growth Pattern

Below is the plot of the Return On Equity of Inozyme Pharma over the last few years. Return on Equity is the amount of Inozyme Pharma net income returned as a percentage of Inozyme Pharma equity. Return on equity measures Inozyme Pharma profitability by revealing how much profit Inozyme Pharma generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. Inozyme Pharma's Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported -0.7910 Years Trend
Slightly volatile
   Return On Equity   
       Timeline  

Inozyme Return On Equity Regression Statistics

Arithmetic Mean0.18
Coefficient Of Variation272.33
Mean Deviation0.44
Median0.50
Standard Deviation0.48
Sample Variance0.23
Range1.1123
R-Value(0.81)
Mean Square Error0.09
R-Squared0.66
Significance0.0002
Slope(0.09)
Total Sum of Squares3.29

Inozyme Return On Equity History

2024 -0.48
2023 -0.51
2022 -0.55
2021 -0.52
2020 -0.35
2019 0.56

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Return On Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Equity(0.51)(0.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.